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Abstract Bcl-xL, a close homolog of Bcl2, is an important
regulator of apoptosis and is overexpressed in human cancer.
Phosphorylation of Bcl-xL can be induced by microtubule-dam-
aging drugs such as taxol or 2-methoxyestradiol (2-ME). By
site-directed mutagenesis studies, we have identi¢ed that serine
62 is the necessary site for taxol- or 2-ME-induced Bcl-xL
phosphorylation in prostate cancer cells. Further studies with
the inhibitor of Jun kinase (JNK) and phosphorylation null mu-
tant of Bcl-xL reveal the augmentative role of JNK-mediated
Bcl-xL phosphorylation in apoptosis of prostate cancer cells. In
summary, our studies suggest that the phosphorylation of Bcl-
xL by stress response kinase signaling might oppose the anti-
apoptotic function of Bcl-xL to permit prostate cancer cells to
die by apoptosis.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The Bcl2 family comprises of two counteracting groups of
proteins: the pro-apoptotic and anti-apoptotic [1^3]. Among
the anti-apoptotic members, Bcl2, Bcl-xL or Mcl-1 gets phos-
phorylated by microtubule disarraying agents such as taxol,
dolastatin 10, nocodazole or 2-methoxyestradiol (2-ME)
[4^25]. The phosphorylation of the Bcl2 family members ren-
dered negative outcome on their biological function [4^32].
Phospho-Bcl2 associates with a member of a peptidyl prolyl
isomerase family, Pin1 and transient conformational change
induced by Pin1 hinders Bcl2 to execute its normal anti-apo-
ptotic activity against tubulin binding drugs [4,24]. The
emerging concept that yielded from these studies is that phos-
phorylation-induced inactivation of Bcl2 protein on Ser70 res-
idue inside the unstructured ‘loop region’ (LR) during mitosis
might work as a checkpoint to augment apoptosis [11,13,15].
The LR of both Bcl2 and its close homolog Bcl-xL can neg-
atively regulate their functions as evident by enhanced anti-
death activity of LR-de¢cient or phosphorylation-defective
mutants [32,33]. The screening of a library of phage-displayed
peptides as well as chemical approach identi¢ed interaction of
taxol with LR of Bcl2 [34,35]. Besides, microtubule-damaging
drugs, growth factor-signaling molecules such as insulin-like
growth factor binding protein-3 (IGFBP-3) can mediate apo-
ptosis induced by TNF-K through the inactivation of the cell
survival protein Bcl2 via serine phosphorylation in prostate
cancer cells PC-3 [36].
Unlike Bcl2, the functional signi¢cance of tubulin binding
drug-induced Bcl-xL phosphorylation remains elusive. We in-
itiated this study on the belief that it is important to determine
the precise site of phosphorylation to dissect out the function-
al consequences of Bcl-xL phosphorylation. Our results indi-
cate that Jun kinase (JNK)-mediated Bcl-xL phosphorylation
on serine 62 residue inside LR of Bcl-xL is critical for render-
ing death advantage against taxol or 2-ME.
2. Materials and methods
2.1. Cell lines and reagents
Human prostate cancer cells DU145 were maintained in minimal
essential medium (MEM) supplemented with 10% fetal bovine serum
(FBS) and 50 Wg/ml gentamicin. Mouse monoclonal antibodies
against Bcl-xL and Bcl2 were purchased from Pharmingen, USA
and Upstate Biotechnology, USA respectively. V-Protein phosphatase
kit was available from New England Biolabs, USA. JNK inhibitor II
was purchased from Calbiochem, USA. Phospho-speci¢c Bcl2 anti-
body was developed in the laboratory as described previously [4]. All
other reagents used were of ultrapure grade.
2.2. Assessment of Bcl2/Bcl-xL phosphorylation
Equal amounts of protein isolated from cells with or without taxol
or 2-ME treatment were subjected to 12% sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) followed by Western
blot. The phosphorylated forms of Bcl2/Bcl-xL protein were detected
as slower migrating forms on Western blots as described previously
[4^9,25]. For detection of phospho-Bcl2, either whole antibody [4^9]
or phospho-Bcl2-speci¢c antibody [4] was used. Dephosphorylation
reaction by V-protein phosphatase was performed in accordance
with the manufacturer’s reaction as described previously [5]. Brie£y,
freshly prepared lysate was incubated at 30‡C for 30 min with 200^
400 units of V-protein phosphatase in a reaction bu¡er containing 50
mM Tris^HCl, 0.1 mM ethylenediamine tetraacetic acid (EDTA),
5 mM dithiothreitol (DTT), 0.01% Brij 35 (pH 7.5, at 25‡C) and
2 mM MnCl2. The reaction was stopped by boiling for 5 min in
Laemmli’s sample bu¡er.
2.3. Cell sorting
Cells were stained with Hoechst 33342 (Sigma) at a concentration
of 15 Wg/ml for 1 h at 37‡C. To increase the resolution of DNA
distribution, 3,3P-dipentyloxacarbocyanineiodide (Molecular Probes)
was added at a concentration of 0.2 Wg/ml simultaneously with
Hoechst 33342 [4,8,9]. Cells were sorted using a £uorescence-activated
cell sorter.
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2.4. Construction of Bcl-xL mutants
We started substitution of several serine and threonine residues in
Bcl-xL protein by site-directed mutagenesis using overlap extension
involving the polymerase chain reaction (PCR) [5,9,37]. The following
sets of overlapping primers were designed from the human Bcl-xL
cDNA clone sequence.
Asterisk indicates mutated nucleotides incorporated in Bcl-xL gene.
Numbers indicate the position of nucleotides in Bcl-xL gene. In addi-
tion to the above overlapping primers, two external primers (5P and 3P
ends of Bcl-xL cDNA) were also synthesized with EcoRI and NotI
extensions respectively.
The PCR products were gel puri¢ed by Qiagen spin column and
digested with EcoRI and NotI restriction enzymes followed by cloning
into pcDNA3 (Invitrogen) at the EcoRI and NotI sites. Mutations in
the clones were veri¢ed by automated DNA sequencing. Wild-type
Bcl-xL was also constructed in pcDNA3 vector by cloning the PCR
ampli¢cation product generated by 5P and 3P end primers and tem-
plate Bcl-xL DNA in pBluescript.
2.5. Transfections of wild and mutant Bcl-xL cDNAs
DU145 prostate cancer cell line (expressing low endogenous level of
Bcl-xL) was stably transfected with pcDNA3 alone or pcDNA3 plas-
mids containing either wild-type or various mutant (Ser/Thr to Ala)
constructs using the calcium phosphate co-precipitation method and
positive clones were selected in G418-containing medium [5,9].
2.6. Determination of apoptosis
Chromatin condensation of 4P,6-diamidino-2-phenylindole dihydro-
chloride (DAPI) (2 Wg/ml)-stained nuclei were scored by epi£uores-
cence microscopy as described previously [8].
3. Results
3.1. Taxol can trigger Bcl-xL phosphorylation in prostate
cancer cells at G2-M phase of cell cycle
Taxol-induced mobility shift of Bcl-xL in mammary cancer
cells is known to be the phosphorylated form of Bcl-xL [25].
We also observe similar mobility shift of Bcl-xL (Fig. 1A, lane
3) in DU145-2 cells (prostate cancer cells genetically engi-
neered to overexpress wild-type Bcl-xL) when exposed to tax-
ol. Panel A (Fig. 1, lane 4) indicates the quantitative conver-
sion of modi¢ed form to unmodi¢ed form of Bcl-xL by V-
phosphatase treatment. V-Phosphatase is an Mnþ2-dependent
protein phosphatase with activity towards phosphorylated ser-
ine, threonine or tyrosine residues [5,15]. Of note, there is no
change of unmodi¢ed form of Bcl-xL by V-phosphatase treat-
ment. The dose^response study reveals that taxol can phos-
phorylate Bcl-xL even at 10 nM concentration (Fig. 1B).
In order to determine when in the cell cycle Bcl-xL phos-
phorylation occurs, taxol-treated cells were sorted after 16 h
into pools of cells into G1-S or G2-M. As shown in Fig. 1C,
lane 1, abundant phosphorylated form of Bcl-xL was present
in G2-M-enriched fraction of cells. We were unable to process
the G1-S fraction of taxol-treated cells because of the low
yield (6 30% cells). The levels of Bcl-xL from unsorted con-
trol and taxol-treated cells were presented in lanes 2 and 3
respectively. These results indicate that anti-cancer drugs that
cause G2-M arrest by a¡ecting microtubule integrity induce
Bcl-xL phosphorylation predominantly at G2-M phase of the
cell cycle.
3.2. Identi¢cation of phosphorylation site on Bcl-xL by
site-directed mutagenesis
To understand the speci¢c Ser/Thr residue(s) required for
taxol-induced Bcl-xL phosphorylation, we started substitution
of several serine and threonine residues (Ser56, Ser62, Thr47,
and Thr115) in Bcl-xL protein with alanine residues by site-
directed mutagenesis [37]. A similar Ser/Thr to Ala substitu-
tion approach was undertaken for determining the phosphor-
ylation site(s) of Bcl2 protein [5,9,11,15,38,39]. We chose these
amino acid residues because they are located within the £ex-
ible loop or in close proximity of this loop. Furthermore,
sequences surrounding these amino acids resemble consensus
motif for SAPK/JNK substrate. SAPK/JNK is known to
phosphorylate Bcl2 in response to taxol [11,15,38].
Cellular extracts from stably transfected wild and mutant
clones were analyzed for the status of taxol-induced Bcl-xL
phosphorylation. Immunoblot analysis using anti-Bcl-xL
monoclonal antibody reveals that only Ser62 to Ala mutation
can abrogate taxol-induced Bcl-xL phosphorylation (Fig. 2A,
lane 2). Other Ser/Thr to Ala mutants were without any e¡ect
(Fig. 2A, lanes 4, 6, 8). Our studies suggest that taxol-induced
Bcl-xL phosphorylation does occur on Ser62 residue (Fig. 2A,
lane 2). Like taxol, another estrogen metabolite 2-ME can
induce Bcl2/Bcl-xL phosphorylation with mitotic arrest in leu-
kemic, breast, prostate or pancreatic cancer cells [18,19,30].
When wild-type Bcl-xL transfected DU145 cells were chal-
lenged with this compound, phosphorylation of Bcl-xL was
clearly evident (Fig. 2B). But no phosphorylation was visible
when S62A mutant overexpressed DU145 cells were exposed
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to 5 WM 2-ME (Fig. 2B). Thus Ser 62 residue appears to be
critical for anti-microtubule agents taxol- and 2-ME-mediated
Bcl-xL phosphorylation.
3.3. JNK pathway is responsible for Bcl-xL phosphorylation
and apoptosis
Similar to Bcl2, the phosphorylation site for Bcl-xL also
conforms to the consensus motif for substrates of MAP kinase
and JNK/SAPK [5,11,15]. By employing dominant negative
mutants of JNK-signaling pathway, Bcl2 was shown to be
phosphorylated by the concerted e¡ort of ASK1/JNK1 in
leukemic or breast cancer cells [11,15]. In order to assess
whether JNK can phosphorylate Bcl2/Bcl-xL in prostate can-
cer cells, a potent cell permeable selective inhibitor of c-Jun
N-terminal kinase (JNK) was used followed by exposure to
taxol. When Bcl2 overexpressing cells, W-34 were treated with
taxol, two slower mobility forms were detected by Bcl2 mono-
clonal antibody (Fig. 3A, lane 3). Of note, both of these slow-
er mobility forms were abolished by V-phosphatase (Fig. 3A,
lane 4) without a¡ecting non-phospho-form (Fig. 3A, lane 2).
V-Phosphatase can even abolish some endogenous phospho-
forms of Bcl2 (Fig. 3A, lane 2). These two slower mobility
forms of Bcl2 emerged due to taxol treatment were also spe-
ci¢cally detected by phospho-speci¢c Bcl2 antibody (Fig. 3B,
lane 2) developed in the laboratory [4]. As shown in Fig. 3B,
lane 1, the endogenous phospho-form of Bcl2 is also detected
by phospho-Bcl2-speci¢c antibody. It is worth mentioning
that others and we can detect endogenous phospho-form of
Bcl2 in cells when ectopically overexpressed [5,15]. The pre-
treatment of JNK inhibitor II can successfully abrogate the
phospho-forms of Bcl2 in a concentration-dependent manner
(Fig. 3B, lanes 3^5). Our inhibitor studies reinstate the in-
volvement of JNK in Bcl2 phosphorylation as observed ear-
lier. Similar to Bcl2, when DU145-2 cells were pretreated with
5^20 WM of JNK inhibitor II, gradual decrease of Bcl-xL
phosphorylation was noted (Fig. 3C and E), which might
also implicate the JNK-signaling pathway in taxol- or 2-
ME-induced Bcl-xL phosphorylation in prostate cancer cells.
This inhibitor is known to e¡ectively block the accumulation
of phospho-Jun in response to cytokines [40,41]. Moreover, it
is noteworthy that the inhibitors of p38 MAP kinase or ERK2
kinase were without any e¡ect on taxol-induced Bcl-xL phos-
phorylation (Fig. 3D). A similar observation was noted in the
case of taxol-induced Bcl2 phosphorylation [15,42].
Next, we examined whether blocking of JNK activity can
prevent taxol or 2-ME initiated cell death in DU145-2 cells.
As shown in Fig. 3F, co-incubation with 10 WM JNK inhib-
itor II rendered the cells more resistant to taxol or 2-ME
triggered apoptosis.
3.4. Serine 62 residue of Bcl-xL is critical for taxol or 2-ME
triggered Bcl-xL phosphorylation and apoptosis
Here we ectopically overexpressed wild as well as Ser62Ala
mutant Bcl-xL by stable transfection to test the e¡ects of 2-
ME and taxol on the extent of apoptosis. Wild, mutant and
vector transfected DU145 cells were challenged with 10 nM
taxol or 5 WM 2-ME followed by determination of apoptosis
[6]. Previously, it has been shown that human prostate carci-
noma cells DU145 lack Bcl2 and are insensitive to 2-ME-
induced apoptosis despite the activation of SAPK/JNK [19].
                        
  
 
  
  
Fig. 1. Tubulin binding agent taxol-induced Bcl-xL phosphorylation at mitotic phase of the cell cycle. A: Taxol induces a modi¢ed form of
Bcl-xL and V-phosphatase can abolish this modi¢ed form. Lanes 1 and 2, dimethyl sulfoxide (DMSO) control; lanes 3 and 4, taxol; lanes 1
and 3, no V-phosphatase addition; lanes 2 and 4, 200 units of V-phosphatase. B: Bcl-xL phosphorylation at di¡erent concentrations of taxol.
C: Immunoblotting of puri¢ed G2-M fraction from taxol-treated DU145-2 clone. Arrow indicates phosphorylated form of Bcl-xL.
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Parallel to this observation, we have noted negligible amount
of Bcl-xL in these cells and very little extent of apoptosis in
response to taxol or 2-ME. Due to overexpression of Bcl-xL,
both 2-ME- and taxol-induced DNA fragmentations were sig-
ni¢cantly more enhanced in DU145-2 clone than vector trans-
fected treated cells. A similar response was observed with
other wild-type (not shown) or other Ser/Thr to Ala Bcl-xL
transfected clones (Fig. 4). In contrast, the overexpression of
phosphorylation null mutant of Bcl-xL resulted in no signi¢-
cant increase in the extent of apoptosis triggered by these anti-
cancer agents. Indeed, the insensitivity of the mutant trans-
fected cells to apoptosis indicates the phosphorylation on ser-
ine 62 residue to be critical for apoptotic signal transduction
cascade triggered by 2-ME or taxol (Fig. 4).
4. Discussion
The investigation reported here demonstrates for the ¢rst
time that Ser62 is the critical site for taxol- or 2-ME-induced
Bcl-xL phosphorylation. In contrary to Bcl2 or Mcl-1, which
can be phosphorylated on multiple Ser/Thr residues
[5,15,21,27,38], Bcl-xL is phosphorylated on single serine res-
idue following taxol exposure and G2-M arrest. Taxol or 2-
ME can cause rapid activation of SAPK/JNK in tumor cell
lines previously tested by others [19,38]. A very recent report
[19] clearly indicated the involvement of SAPK/JNK in 2-ME-
induced Bcl2 phosphorylation and apoptosis in several com-
mon epithelial carcinoma cells. The inhibitory e¡ect of JNK
inhibitor on taxol or 2-ME triggered Bcl-xL phosphorylation
                            
Fig. 2. E¡ect of microtubule disrupting agents on the phosphorylation status of several Ser/Thr to Ala mutants of Bcl-xL. A: Serine 62 to ala-
nine point mutation abolishes taxol-induced Bcl-xL phosphorylation. Wild and several Ser/Thr to Ala Bcl-xL constructs were stably transfected
in DU145 prostate cancer cells. Cells were exposed to 100 nM taxol for 16 h. Cellular extract was subjected to immunoblot analysis with Bcl-
xL antibody. Lanes 1, 3, 5, 7, 9 and 11, DMSO treatment; lanes 2, 4, 6, 8, 10 and 12, 100 nM taxol treatment for 16 h. Lanes 1 and 2, Ser62-
Ala mutant; lanes 3 and 4, Ser56Ala mutant; lanes 5 and 6, Thr115Ala mutant; lanes 7 and 8, Thr47Ala mutant; lanes 9 and 10, DU145
(neo) cells; lanes 11 and 12, DU145-2 clone. B: S62A Bcl-xL mutant can also abrogate 2-ME triggered Bcl-xL phosphorylation. Arrow indi-
cates phosphorylated form of Bcl-xL.
C
Fig. 3. JNK inhibitor can diminish taxol- or 2-ME-induced Bcl2/Bcl-xL phosphorylation as well as apoptosis. A: V-Phosphatase (V-PPase) can
abolish only taxol-induced slower mobility forms of Bcl2 in W-34 cells. Western blot was carried out with monoclonal antibody against Bcl2
that recognizes both non-phospho- and phospho-forms of Bcl2. In vitro V-phosphatase assay was performed using cellular extract isolated from
Bcl2 overexpressing prostate cancer cells. Reduction of taxol-induced phosphorylation of Bcl2 (B) and Bcl-xL (C) in cells pretreated with JNK
inhibitor II. D: Lack of inhibitory e¡ect of PD98059 (ERK2 inhibitor) or SB202190 (p38 MAP kinase inhibitor) on taxol-induced Bcl-xL phos-
phorylation. W-34 cells (PC-3 cells engineered to overexpress Bcl2) or DU145-2 cells were pretreated with either JNK inhibitor II (5^20 WM) or
PD98059 (100 WM) or SB202190 (1^10 WM) followed by treatment with taxol. For analyzing Bcl2 phosphorylation (B), phosphorylation site-
speci¢c Bcl2 antibody [4] was used. For Bcl-xL we have used Bcl-xL monoclonal antibody. E: E¡ect of JNK inhibitor II on 2-ME triggered
Bcl-xL phosphorylation. DU145-2 cells were either pretreated or not pretreated with 10 WM JNK inhibitor II for 8 h followed by treatment
with 5 WM 2-ME for 16 h. F: E¡ect of JNK inhibitor II on taxol- or 2-ME-induced apoptosis. Apoptotic nuclei were visualized by DAPI
staining. Approximately 500 cells were scored in each category. Results are meansRS.D. of three independent experiments.
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as well as on the concomitant apoptosis establishes the role of
SAPK/JNK signaling in Bcl-xL phosphorylation. But our
studies do not rule out the possibility of the involvement of
other upstream kinase of JNK as reported earlier in the case
of p53-mediated Bcl2 phosphorylation and its inactivation
[27]. Interestingly, like Bcl-xL, not only Bcl2 but also another
anti-apoptotic member of Bcl2 family, Mcl-1, is inactivated by
JNK-mediated phosphorylation in response to oxidative stress
[21]. It is worth mentioning that parental DU145 and DU145-
2 cells do not express other anti-apoptotic members such as
Bcl2. Moreover, Bcl-xL is completely phosphorylated by taxol
or 2-ME in these cells. The lack of expression of Bcl2 and
inactivation of Bcl-xL by phosphorylation can be the key
factors for DU145-2 cells to die. If phosphorylated form of
Bcl-xL could protect, one would note similar or lesser extent
of cell death than parental DU145 cells. But we have rather
observed the greater extent of cell death (Fig. 4) in wild-type
Bcl-xL overexpressing cells. In contrast, Ser62Ala mutant ex-
pressing clone but not other Ser/Thr to Ala mutant clones
were relatively resistant to taxol- or 2-ME-induced cell death.
Our observation clearly suggests that Bcl-xL phosphorylation
in response to taxol or 2-ME permits cells to undergo apo-
ptosis. Conceivably, the greater extent of the presence of Bcl-
xL containing Ser62 residue is more responsive to taxol- or 2-
ME-induced apoptosis of prostate cancer cells. Our observa-
tion is quite concordant with a recent study on Bcl2 phos-
phorylation with a population of breast tumors. Intriguingly,
83% of breast tumors with high phospho-Bcl2 expression were
sensitive to treatment to paclitaxel or docetaxel [43]. In con-
trary, 57% of tumors with low phospho-Bcl2 expression did
not respond to taxane therapy. Together these ¢ndings sug-
gest that pS70 Bcl2 or pS62 Bcl-xL might be a predictive
factor for prognosis and sensitivity to 2-ME or paclitaxel
treatments.
The susceptibility to apoptosis is an essential prerequisite
for the successful elimination of cancer cells [44]. Apoptosis is
the outcome of the activation of a family of cysteine proteases
called caspases [45,46]. Two di¡erent major pathways basi-
cally activate caspases: (a) one pathway is linked to TNF
family of death receptors [47], (b) another is mediated through
mitochondria [45,48]. Both taxol and 2-ME elicited apoptosis
occurs through mitochondria [13,30]. Apparently, activated
JNK also acts on mitochondria and induces apoptosis
through the release of cytochrome c into cytosol [49]. Thus
the members of Bcl2 family located in mitochondria are the
potential targets of translocated phospho-JNK. It was re-
ported earlier that activated phospho-JNK can translocate
to mitochondria to associate with Bcl-xL in response to phor-
bol ester [50].
The studies depicted here have potential clinical signi¢-
cance. The anti-apoptotic protein Bcl-xL plays an important
role in tumor cell survival. The overexpression of Bcl-xL in
chemo-resistant tumors is well known [1]. The potential apo-
ptosis yielding e¡ects of phospho-Bcl-xL by tubulin binding
drugs to render its inactivation will be de¢nitely helpful to
identify another molecular target.
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